EV20/NMS-P945, a Novel Thienoindole Based Antibody-Drug Conjugate Targeting HER-3 for Solid Tumors

HER-3 is becoming an attractive target for antibody–drug conjugate (ADC)-based therapy. Indeed, this receptor and its ligands are found to be overexpressed in several malignancies, and re-activation of its downstream signaling axis is known to play a critical role in modulating the sensitivity of ta...

Descripción completa

Detalles Bibliográficos
Autores principales: Capone, Emily, Lattanzio, Rossano, Gasparri, Fabio, Orsini, Paolo, Rossi, Cosmo, Iacobelli, Valentina, De Laurenzi, Vincenzo, Natali, Pier Giorgio, Valsasina, Barbara, Iacobelli, Stefano, Sala, Gianluca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066800/
https://www.ncbi.nlm.nih.gov/pubmed/33918158
http://dx.doi.org/10.3390/pharmaceutics13040483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8066800/
https://www.ncbi.nlm.nih.gov/pubmed/33918158
http://dx.doi.org/10.3390/pharmaceutics13040483

Ejemplares similares